From eye to mind
Researchers are also looking to the eye for early biomarkers of neuropsychiatric disease, which could enable clinicians to intervene before their onset or thwart their progression. For instance, there is evidence that, in people with schizophrenia, the small veins, or venules, of the retina are wider and the retina is thinner4.
This sounds like a good thing.
Maziade is confident that electroretinography will soon enter the clinic. In 2015, he co-founded diaMentis, a personalized-medicine company in Quebec City that is developing software for electroretinography-signal analysis. Within three years, Maziade says, the company’s software should be advanced enough to help clinicians to make accurate diagnoses of schizophrenia.